MDPI

Sweet Dreams (Are Made of This): A Review and Perspectives on Aspartic Acid Production

Holly Appleton and Kurt A. Rosentrater *

Department of Agricultural and Biosystems Engineering, College of Engineering, Iowa State University, Ames, IA 50011, USA; hjapplet@ncsu.edu
* Correspondence: karosent@iastate.edu

Abstract: Aspartic acid, or "aspartate," is a non-essential, four carbon amino acid produced and used by the body in two enantiomeric forms: L-aspartic acid and D-aspartic acid. The L-configuration of amino acids is the dominant form used in protein synthesis; thus, L-aspartic acid is by far the more common configuration. However, D-aspartic acid is one of only two known D-amino acids biosynthesized by eukaryotes. While L-aspartic acid is used in protein biosynthesis and neuro-transmission, D-aspartic acid is associated with neurogenesis and the endocrine system. Aspartic acid production and use has been growing in recent years. The purpose of this article is to discuss various perspectives on aspartic acid, including its industrial utility, global markets, production and manufacturing, optimization, challenges, and future outlook. As such, this review will provide a thorough background on this key biochemical.

1. Industrial Utility

In addition to its biofunctionality, aspartic acid has wide application in the food, beverage, pharmaceutical, cosmetic, and agricultural industries [1]. L-aspartic acid is used as a nutritional supplement in both functional foods and beverages, but its primary use is in combination with the amino acid phenylalanine which together make aspartame, an artificial sweetener [2]. Aspartic acid is also used to bolster immune function and as a natural combatant to depression [1]. Its ability to aid in energy production, fatigue resistance, RNA and DNA synthesis, and liver detoxification give it broad clinical use [1]. Additionally, it is used as an intermediary substrate in the manufacture of pharmaceuticals and organic chemicals, serving as the building block molecule for active pharmaceutical ingredients [1]. Aspartic acid's utility stretches further upon consideration of its derivatives including acetyl aspartic acid, used as an active ingredient in anti-aging cosmetics that target wrinkling, skin lifting, and loss of firmness [3]. It is also used to produce polyaspartic acid, a fertilizer synergist which increases both nitrogen absorption and crop yields [4]. Polyaspartic acid hydrogels are a type of biodegradable superabsorbent polymer which have exceptional water-holding abilities and are used in the production of many modern amenities including diapers, feminine products, and engineered tissue [5]. The range and depth of aspartic acid's applicability, in particular the L-configuration, has placed it on the Department of Energy's Top Value Added Chemicals from Biomass list [2].

2. Global Markets

The global aspartic acid market is a highly fractionated market meaning it consists of several small company players rather than large conglomerates, yet it is growing with significant potential for industrial relevance [6]. According to a 2015 report by Grand View Research, the global aspartic acid market is projected to reach $101 million with a market demand of 60.6 kilotons by 2022 which represents a compound annual growth rate of 5.6% [6]. As of 2014, the baseline year of said report, polyaspartic acid represented

22.6% of the total aspartic acid market volume making it the largest market segment, seconded by aspartame [6]. Both aspartic acid derivatives are anticipated to increase in demand as polyaspartic biodegradable polymers replace polyacrylic acid in agriculture, water treatment, and the petrochemical industries and as food and beverage trends shift towards added sugar labeling and health-conscious, convenience foods [6]. Of all aspartic acid market sectors, the medical sector is projected to grow the most as is attributed to the American healthcare system, which is housed in the largest regional market, accounting for 39.0% of total aspartic acid volume as of 2014 [6]. Internationally increased demand for aspartic acid is also expected to increase in the form of greater aspartame demand for carbonated beverages in Asia Pacific [6].

3. Production and Manufacturing

There are three main methods to produce aspartic acid: protein extraction, chemical synthesis, and enzymatic conversion [2]. The hydrolysis of protein for extraction methods produces an abundance of amino acids from which the L-aspartic acid must be separated. Chemical synthesis requires high temperature and pressure and results in a racemic mixture, producing both L- and D-isomers thereby requiring the additional processing steps of optical resolution and racemization to achieve the preferred L-isomer [1]. Thus, enzymatic conversion is the currently favored route of production. The enzymatic conversion process exists in two forms: simple enzyme-substrate interaction (hereafter referred to as "enzymatic conversion") or whole-cell enzymatic conversion, i.e., fermentation. Table 1 summarizes various economic and technical aspects of the production of aspartic acid.

Stereospecific, industrial production of L-aspartic acid currently utilizes a one-step reaction of fumaric acid, in the presence of high concentrations of ammonia, to L-aspartic acid via L- aspartate ammonia-lyase, an enzyme also referred to as "L-aspartase" (Figure 1) [7]. L-aspartase can be purified and immobilized in a gel matrix for continuous production or overexpressed in bacterial cells bound to polyurethane carriers [7]. Production via immobilized enzymatic conversion or bacterial fermentation utilizes the same enzyme and substrate; however, enzymatic production is favored for its high product concentration, productivity, minimal byproducts, and the ease of downstream processing [2]. Yet, fermentative production, albeit less productive, has been around since the 1950s when research and development into the production of aspartic acid began [8].

While several species of bacteria including select Pseudomonas, Bacillus, and Proteus have been identified as producers of aspartic acid, *E. coli* and *Cornybacterium glutamacium* are nearly exclusively used by industry [1,9]. Fumaric acid is the primary substrate in L-aspartic acid production; however, maleate, a less expensive feedstock, can be used in a two-step reaction which uses maleate isomerase to convert maleate to fumaric acid which is then converted via L-aspartase to L-aspartic acid in the presence of ammonium ions [8].

The basic fermentation process, as developed and patented in the 1960s, utilizes a sugar-free medium wherein fumaric acid is the sole source of carbon subsequently minimizing the production of unwanted byproducts [10]. Ammonia, while required for catalysis, also serves as the nitrogen source and is formulated at a 1:1 or 1:2 fumaric acid-ammonia ratio [10]. Prior to inoculation, the broth pH is initialized to 7.0 and left unregulated as it will naturally increase to a 8.4–9.6 range in the initial stages of the fermentation, allowing for the production of acid [10].


Figure 1. Chemical mechanism of aspartic acid production (based, in part, on [8]).

Table 1. Summary of Aspartic Acid Supply Chain, Economic and Technological Considerations for Aspartic Acid Production.

Category	Summary
Industrial importance and potential of biochemical	Aspartic acid is used in the food, beverage, pharmaceutical, cosmetic, and agricultural industries. The global aspartic acid market is projected to reach $101 million with a market demand of 60.6 kilotons by 2022 representing a compound annual growth rate of 5.6% [6].
Industrial uses for biochemical	Aspartic acid is used in the production of: nutritional (amino acid) supplements; artificial sweetener (aspartame); polyaspartic acid hydrogels; and acetyl aspartic acid, the active ingredient in anti-aging cosmetics.
Substrates used for the production of biochemical	**primary substrate:** fumaric acid [7] **cofactor:** ammonia [7] **enzyme:** L-aspartate ammonia-lyase [7]
Microorganisms used for fermentation	**Primary industrial species:** *E. coli* and *Cornybacterium glutamacium* [9] **Exploratory species [1]:** *Pseudomonas aeroginosa* *Pseudomonas fluorescens* *Candida hydrocarbofumarica* *Bacillus stearothermophilus* *Bacillus subtilis*
What enzymes are needed to break down the substrate for fermentation	Fumaric acid used in aspartic acid production does not need to be broken down, rather, it is fermentatively produced from glucose or chemically produced from maleic anhydride [6].
Fermentation conditions used: pH, substrate loading, temperatures, times, maximum yield, maximum fermentation rates	**pH** is initialized to 7.0 [10] **substrate concentration**: 1:1 or 1:2 ammonia to fumaric acid [10] **time** 2 to 10 days [10] **temperature** 27–40 °C [10] **yield** 77–95% (*w/w* of fumaric acid) depending on bacterial strain and fermentation conditions [10]
Separation equipment, conditions, efficiencies	**batch fermentation:** separation via anion exchange column and crystallization [10] **continuous fermentation:** separation via isoelectric point precipitation and crystallization [10]
Total energy used to produce this chemical	*Data not currently published.*
Estimated costs to produce this chemical	Cost as well as upstream and downstream raw materials and equipment analysis available in the global L-aspartic acid market report provided by Market Watch (2019), at https://www.researchreportsworld.com/purchase/14314090 (accessed on 21 February 2021)

Table 1. *Cont.*

Category	Summary
Current aspartic acid manufacturers	The following companies are the top industrial producers of aspartic acid [11]; the corresponding links, when applicable, are to each respective company's product information page. **Ajinomoto Group** https://www.ajiaminoacids.com/product/l-aspartic-acid (accessed on 21 February 2021) **Evonik** https://healthcare.evonik.com/product/health-care/en/products/pharmaceutical-amino-acids/REXIM/pages/parenteralnutrition.aspx?xd_co_f=M2Q2OWQ5N2ItYTZkOC0 0ZWZjLThjNmUtODFiYjQ3YmYwM2I2 (accessed on 21 February 2021) **KYOWA** http://www.kyowahakko-bio.co.jp/english/products/aminoacids/l_aspartic_acid/ (accessed on 21 February 2021) **Jinghai Amino Acid** http://en.chinaaminoacid.com/products/L-AsparticAcid.shtml (accessed on 21 February 2021) **JIRONG PHARM** Not currently available OR product catalogue not in English **Siwei Amino Acid** English product description not available **Zhangjiagangxingyu Technology** http://www.zjgxykj.com/template/p13e.html (accessed on 21 February 2021) **Hubei Bafeng Pharmaceutical** Company page not accessible in English
Potential market segments, sales, etc.	The aspartic acid market is segmented into six market categories: Feed Supplements, Medicine, Polyaspartic Acid, Aspartame, L-Alanine, and "Others" [6]. The report summary states that polyaspartic acid represents 22.6% of the total market volume in 2014. Market volumes and revenue values available upon report purchase [11].
Primary economic setbacks and challenges	Fermentative production competes economically with petroleum-derived production. Economic setbacks of aspartic acid include high fumaric substrate cost and the low yields currently achieved by switching to cheaper sugar-based feedstocks [10]. Crystallization utilized in downstream processing separations can be expensive and time-consuming [1].
Technological setbacks and challenges	The fermentative production of aspartic acid from glucose or sugar-based feedstocks, both much cheaper and more available substrates than fumarate, currently generate much poorer yields, i.e., 95% versus 29% [8]. Thus, the main technological setback to more economical aspartic acid production is the ability to directly ferment sugar to L-aspartic acid.

Table 1. *Cont.*

Category	Summary
Side products, byproducts, waste products and associated cost	Organisms whose genomes also code fumarase (e.g., *C. glutamicum*, *E. coli*) produce malic acid from fumarate as a byproduct in effect utilizing substrate and decreasing aspartic acid yield. Without heat treatments Tajima et al. (2015) lost 25% of the fumaric acid substrate to malic acid production which translates to significant yield losses [7].
Downstream processing operations	L-aspartic acid can be separated from the culture broth or eluate in batch systems via ion exchange resins utilizing an anion exchange column followed by crystallization of the eluate [1]. Continuous systems can extract the L-aspartic acid via isoelectric point precipitation (adjust broth pH to 2.8) followed by crystallization [10].
New technologies, strains, equipment developments	Membrane reactor systems (MRS), as they are currently being developed, utilize growth-arrested cells eliminating the need for cell or enzyme immobilization [8]. The MRS system employed by Yukawa et al. (2009) overcomes the low mass transfer rates and low volumetric productivity issues associated with immobilization systems and simplifies the overall production process, allowing for easier separation of cells from the reaction mixture and generating high yield and productivity during long periods of operation [8]. Genetic modification of the metabolic pathways and feedback regulators within *E. coli* and *C. glutamicum*, the two major strains involved in industrial amino acid synthesis, are the next steps in improving L-aspartic acid production via the development of new, high-producing strains.

Fermentation can be conducted with or without agitation for 2 to 10 days at 27–40 °C [10]. The L-aspartic acid will be extracellularly secreted and accumulate in the culture broth [10]. Several methods of downstream processing are available to separate L-aspartic acid from the culture broth or eluate. In the case of batch fermentation, ion exchange resins can be used to separate and purify the L-aspartic acid on an anion exchange column followed by crystallization of the eluate (Figure 2). For continuous fermentation, L-aspartic acid can be separated by adjusting the broth to 90 °C and a pH of 2.8 with sulfuric acid [10]. Adjusting the pH to 2.8, i.e., the isoelectric point, will cause L-aspartic acid to precipitate out of solution where it is then subjected to a two hour incubation period at 15 °C to induce protein crystallization [10]. Under these conditions, 95% of the theoretical yield of L-aspartic acid was achieved by Masahiro et al. (1965) which aligns with the 77–95% yield range achieved similar fermentation processes utilizing various bacterial strains [1,10]. Table 2 provides commonly used L-aspartic acid fermentation parameters.


Figure 2. Example amino acid fermentation and downstream process flowchart adapted from Leuchtenberger et al. (2005) [12].

Table 2. Specific Production Parameters for the Fermentative Synthesis of Aspartic Acid.

	Yukawa et al. (2009) [8]	Tajima et al. (2015) [7]	Chibata et al. (1986) [13]	Szymanska et al. (2011) [14]	Papierz et al. (2007) [15]
Pretreatments and Conditions Used	Genetically modify *C. glutamicum* to overproduce maleate isomerase and aspartase	*E. coli* DH5 used to produce plasmid containing aspA gene which is inserted into *S. livingstonensis*; sonicate then heat treat cells	Entrap *E. coli* in polyacrylamide gel via polymerization reaction then break gel in 3–4 mm diameter granules; wash granules in water	Immobilize cells in chitosan gel; culture in FF medium for biomass cultivation (or other chemically defined media as outlined on pg. 2)	Cell membrane permeabilization activates cells prior to aspartic acid production; perfomed in activation medium (chemically defined pg. 2) at 37 °C for 48 h
Substrate Used	Maleate ammonium	fumarate-NH$_3$	1 M ammonium fumarate used for aspartic acid production by immobilized aspartase but no mention if substrate changed in subsequent trials	ammonium fumarate	fumaric acid
Substrate Loadings	Specifics not published	860 mM fumarate-NH3 solution (pH 9)	417 mM/h ammonium fumarate used for aspartic acid production by immobilized aspartase no mention if substrate loading changed in subsequent trials	150.0 g/L ammonium fumarate	100g/L fumaric acid 1 g biomass into 10 mL production media
Enzymes Used	maleate isomerase, aspartase	Enzymes are generated intracellularly	intracellular aspartase	intracellular aspartase	intracellular aspartase
Enzyme Loadings	Specifics not published	Not applicable	Not applicable	Not applicable	Not applicable
Reaction Times	production is continuous	1–2 h	enzyme activity observed after 24–48 h found in production media; however, production can expands weeks in a continuous reactor	>603 h (production can be continuous)	18–30 h
Bioreactor Conditions	pH 8.5 Temp 30 °C	Heat treatment prior to fermentation performed in water bath; optimal conditions were 50 °C for 15 min	intended for continuous production; pack cells in a column reactor	biocatalyst bed height to volume ratio = 3:1; liquid hour space velocity value was 5.2 (i.e., volume of feeding substrate passed per volume of catalyst in bioreactor per one hour)	100 mL shake flasks
Microorganisms Used	*C. glutamicum*	*S. livingstonensis*	*E. coli* ATCC 11303	*Escherichia coli* mutant strains B-715 and P1	*Escherichia coli* mutant strain B-715
Fermentation Conditions Used (Temp, pH, etc.)	pH 8.5 Temp 30 °C	whole cell production set at 37 °C for 3 h	Temp 37 °C half-life of column was 120 days	initial media pH 8.5 Temp 40 °C	initial media pH 8.5 Temp 37 °C
Separation Technologies Used	ultrafiltration	centrifugation, supernatant separated by HPLC with RI detector and ion exclusion column	Specifics not published	HPLC	HPLC

Table 2. *Cont.*

	Yukawa et al. (2009) [8]	Tajima et al. (2015) [7]	Chibata et al. (1986) [13]	Szymanska et al. (2011) [14]	Papierz et al. (2007) [15]
Separation Conditions Used	Specifics not published	Eluate at 60 °C using 0.1% (*v/v*) phosphoric acid for mobile phase with 0.7 mL/ min. flow rate; quantify via derivatization with DNFB	Specifics not published	HPLC with 250–4 LichrospherTM 100RP-18 (Merck) column and Waters fluorescence detector	Deproteinize with methanol, centrifuge, then run on HPLC column set to a flow-rate of 1 mL/min, 22 °C, and 2100 PSI with mobile phase of 200 mL methanol and 800 mL 0.05 M sodium phosphate buffer
Biochemical Yields Achieved	"High yield and productivity" hints that it should be within >95% range as achieved by immobilized cell methods; however, specifics not published	95.2–99.3%	Immobilized aspartase had 29% activity yield but this "activity yield and the stability of the immobilized enzyme were not satisfactory for industrial purposes" thus the need to increase yield from this starting point in subsequent trials; for the set of conditions listed here, the results only mention that activity was notably increased	99.8% conversion rate 6 g L-aspartic acid/g of cells /hour	0.19–0.35 g L-aspartic acid/g of dry biomass/min during 1 h of biosynthesis
Inhibitory Compounds Observed, Developments and Impacts	L-malic acid is a byproduct (reduces yield) which can be avoided by inactivating fumarase via incubation at 45 °C for 5 h	L-malic acid also major byproduct (reduces yield)	Increased membrane permeability to substrate ("activation") and later product increases enzyme activity and is the result of autolysis of the cells in the gel; Tween 80 required for *E. coli* P1	Better immobilization and aspartic acid production with added surfactants for cell activation and a media 2-fold lower in yeast extract (found to be an inhibitory ingredient for biomass production)	Improved production following incubation in the activation medium containing 5 g/L ammonium fumarate
Notes	Incredibly limited in method detail and results	Exact methodology published, even greater detail in literature since multiple fermentation conditions were tested.	Review is very dated (1986); however, it covers several additional methods utilizing different gels and optimized parameters of base method. It appears to contain foundational work from which the popular immobilization technique of aspartic acid production was developed.	Highly detailed methodology	L-aspartic acid production was used to determine best aspartase-active mutant strain, i.e., conditions may not reflect requirements for scaled-up industrial production

4. Optimization

Traditional fermentation setups have since been adapted and optimized to increase productivity and process efficiency. Most notable is the development of continuous systems such as the one employed by Tosa et al. (1973) using immobilized *E. coli* on a cell column. Tosa et al. found production to be optimal at pH 8.5, 50 °C, and a maximized media flow rate of space velocity, i.e., the ratio of volumetric flow rate to reactor volume, of 0.8 [16]. Further process improvement included fortification of the fermentation medium with divalent cations (Mg^{+2}, Mg^{+2}, Ca^{+2}) as was found to protect cells from heat inactivation subsequently increasing the stability of the column [16].

More recently, membrane reactor systems (MRS) are being developed, the use of growth-arrested cells eliminating the need for immobilization (Figure 3) [8]. The MRS system employed by Yukawa et al. (2009) overcomes the low mass transfer rates and low volumetric productivity issues associated with immobilization systems and simplifies the overall process, allowing for easier separation of cells from the reaction mixture and generating high yield and productivity during long periods of operation [8]. While industrial L-aspartic acid production began with immobilized enzymes or cells, it has progressed to include both fermentative and membrane reactor systems [8].


Figure 3. Example membrane reactor system for continuous production of aspartic acid (adapted from [8]).

5. Challenges

According to the U.S. Department of Energy, the major challenges confronting the development of biomass-generated L-aspartic acid as a major chemical building block for the synthesis of multiple high-value biochemicals and materials include: the development of an economically comparable, direct fermentation process from sugar to L-aspartic acid or reduction in the cost of fumaric acid for current production methods [2].

Fermentable sugars are the target substrate for L-aspartic acid production due to their abundance and low cost but are not yet realizable due to the low yields currently achieved [8]. Production of L-aspartic acid from fumaric acid is a one-step reaction and is currently preferred for its higher yields, achieving over 95% yield as compared to 29% from fermentable sugars [8]. While the market price and operational expenses of L-aspartic acid production and its substrates are not free-access, the cost reduction in transitioning from a fumaric acid substrate to glucose or other sugar from biomass represents a significant— nearly 4.5 times less expensive—cost saving as seen by comparing the 2020 retail price of PharmaGrade fumaric acid to USP grade dextrose [17]. However, such cost savings cannot be capitalized upon until improvements in the yield of sugar-based L-aspartic acid fermentation are achieved.

The fermentative synthesis of L-aspartic acid from glucose occurs via the direct conversion of oxaloacetate or fumarate, two interconvertible intermediates within the citric acid cycle, into L-aspartic acid [18]. The maximum theoretical yield based on sugar reducing

equivalents from either aforementioned intermediate is 2 mol L-aspartic acid per 1 mol glucose [18]. Direct fermentation of glucose to L-aspartic acid is rarely reported within the literature and when so, the associated yields are low even for known aspartic acid producing strains, e.g., *Brevibacterium flavum* and *Corynebacterium glutamicum* were reported to produce 0.30 mol and 1.02 mol L-aspartic acid per mol glucose, respectively [18]. Work involving metabolic engineering to maximize L-aspartic acid yield on glucose, in particular within industrially relevant strains such as *E. coli*, is severely lacking.

Recent work by Piao et al. (2019) has demonstrated that cost-effective fermentation of L-aspartic acid from biomass is possible through the use of metabolically engineered *E. coli* and as such is the first work to demonstrate metabolic optimization achieving substantive yields of L-aspartic acid production from glucose [18]. Piao et al. were able to generate a final titer of 33.1 g/L for a 21 h fed-batch fermentation which correlates to a yield of 1.01 mol/mol glucose, i.e., approximately 50% of the maximum theoretical yield [18]. While successful proof-of-concept of an efficient route for the production of L-aspartic acid within *E. coli*, this groundbreaking work elicits the need for further studies that address two current challenges in the production of maximal stoichiometric yields of L-aspartic acid.

First, L-aspartic acid is an intermediate for a wide array of downstream metabolic reactions and the precursor molecule to over ten different metabolic pathways thereby making it difficult to accumulate large quantities of L-aspartic acid mid-metabolism [18]. Further studies need address this bottleneck through metabolic redesign that favors L-aspartic acid accumulation or the development of fermentation strategies that target production of the final L-aspartic acid derivative generated via irreversible reactions. The second challenge is to identify the key to maximum theoretical yield of L-aspartic acid via fermentative synthesis which is currently not known due to the function of its precursor molecule, oxaloacetate, as a critical molecule within several carbon metabolic pathways including glycolysis and gluconeogenesis. This missing key to comprehensive metabolic design strategy makes identification of key bottlenecks in L-aspartic acid accumulation complex and as yet, unelucidated [18]. In addition to designing an optimized metabolic pathway, optimization of a fermentation strategy, growth media, and operational parameters to support the growth and physiological metabolism of *E. coli* genetically modified for L-aspartic acid production needs to be developed [18].

Until such improvements are met, reducing the production cost of fumaric acid is the most economical alternative. Like aspartic acid synthesis, fumaric acid is metabolically produced from oxaloacetate which is converted to malic acid by malate dehydrogenase and then to fumaric acid via fumarase [19]. Several microbial species naturally synthesize fumaric acid, but Rhizopus, a type of saprophytic fungi, are considered the best producer for industrial scalability [19]. Engel et al. (2008) investigated fermentative fumaric acid production from glucose as compared to petroleum-based chemical synthesis. While the fermentative process yields are lower than chemical synthesis (85% *w/w* versus 112% *w/w*) and the cost effectiveness of fermentation heavily dependent on the price of both oil and glucose, the fermentation pathway shows economic potential especially considering the additional process efficiencies achievable with metabolic engineering [20]. Thus, critical developments in the production of fumaric acid particularly in regard to strain improvement, fungal morphological control, cheaper substrate utilization, as well as upstream and downstream yield and process efficiencies [19] will have a trickle-down effect upon the production of aspartic acid.

6. Summary and Future Outlook

The development of bio-based chemicals and processes represents an invaluable opportunity in the protection of natural resources, reduced reliance on limited fossil fuels, and byproduct optimization. Aspartic acid plays a role in the development of resource sufficiency as a biodegradable superabsorbent polymer, a natural source of protein, and as a renewable pharmaceutical, nutritional, and cosmetic compound. While continuous columns and membrane reactor systems have advanced aspartic acid production from

where it began in the 1950s, future developments taking advantage of modern genetic modification and engineering can direct its future as a bio-based building block to meet increasing market demand. In order to be competitive against petrochemically derived aspartic acid, bio-based production calls for improvements in direct fermentative production, i.e., development of a one-step glucose to aspartic acid process; reducing the cost of fumaric acid; increasing sugar-based fermentation yields.

References

1. Kumar, P.; Nika, B.; Mangala, D. Production of Aspartic Acid—A Short Review. *Int. J. Eng. Trends Technol.* **2017**, *45*, 254–257. [CrossRef]
2. Werpy, T.; Petersen, G. *Top Value Added Chemicals from Biomass: Volume I—Results of Screening for Potential Candidates from Sugars and Synthesis Gas*; US Department of Energy: Washington, DC, USA, 2004.
3. Mavon, A. Acetyl Aspartic Acid, a Novel Active Ingredient, Demonstrates Potential to Improve Signs of Skin Ageing: From Consumer Need to Clinical Proof. *Int. J. Cosmet. Sci.* **2015**, *37*, 1–2. [CrossRef] [PubMed]
4. Kinnersley, A.M.; Koskan, L.P.; Strom, D.J.; Meah, A.R.Y. Kingenta. Polyaspartic Acid. US Patent US5593947A, 14 January 1997. Available online: http://en.kingenta.com/Goods/good_show/cid/30/sid/30.html (accessed on 14 February 2020).
5. Meng, H.; Zhang, X.; Chen, Q.; Wei, J.; Wang, Y.; Dong, A.; Yang, H.; Tan, T.; Cao, H. Preparation of Poly(Aspartic Acid) Superabsorbent Hydrogels by Solvent-free Processes. *J. Polym. Eng.* **2015**, *35*, 647–655. [CrossRef]
6. Global Aspartic Acid Market by Application (Feed Supplements, Medicine, Polyaspartic Acid, Aspartame, L-Alanine) Expected to Reach USD 101.0 Million by 2022: Grand View Research, Inc. Available online: https://www.grandviewresearch.com/press-release/global-aspartic-acid-market (accessed on 14 February 2020).
7. Tajima, T.; Hamada, M.; Nakashimada, Y.; Kato, J. Efficient Aspartic Acid Production by a Psychrophile-based Simple Biocatalyst. *J. Ind. Microbiol. Biotechnol.* **2015**, *42*, 1319–1324. [CrossRef] [PubMed]
8. Yukawa, H.; Ookino, S.; Inui, M. L-Aspartic Acid, Production Processes. In *Encyclopedia of Industrial Biotechnology*; Wiley: Hoboken, NJ, USA, 2010; pp. 1–3.
9. Li, Y.; Wei, H.; Wang, T.; Xu, Q.; Zhang, C.; Fan, X.; Ma, Q.; Chen, N.; Xie, X. Current Status on Metabolic Engineering for the Production of l-aspartate Family Amino Acids and Derivatives. *Bioresour. Technol.* **2017**, *245*, 1588–1602. [CrossRef] [PubMed]
10. Masahiro, T.; Yasoji, M.; Shinji, O.; Moriyoshi, I.; Tetsuo, H. Process for Producing l-aspartic Acid. *U.S. Patent US2953499A*, 1965.
11. L-aspartic Acid Market 2019 Global Industry Demand, Recent Trends, Size and Share Estimation by 2025 with Top Players—ResearchReportsWorld.com. Available online: https://www.marketwatch.com/press-release/l-aspartic-acid-market-2019-global-industry-demand-recent-.trends-size-and-are-estimation-by-2025-with-top-players---researchreportsworldcom-2019-06-18 (accessed on 18 June 2019).
12. Leuchtenberger, W.; Huthmacher, K.; Drauz, K. Biotechnological Production of Amino Acids and Derivatives: Current Status and Prospects. *Appl. Microbiol. Biotechnol.* **2005**, *69*, 1–8. [CrossRef] [PubMed]
13. Chibata, I.; Tosa, T.; Sato, T. Continuous Production of L-aspartic Acid. *Appl. Biochem. Biotechnol.* **1986**, *13*, 231–240. [CrossRef]
14. Szymańska, G.; Sobierajski, B.; Chmiel, A. Immobilized Cells of Recombinant *Escherichia coli* Strain for Continuous Production of L-aspartic Acid. *Pol. J. Microbiol.* **2011**, *60*, 105–112. [CrossRef] [PubMed]
15. Papierz, M.; Gadomska, G.; Sobierajski, B.; Chmiel, A. Selection and Activation of *Escherichia coli* Strains for L-aspartic Acid Biosynthesis. *Pol. J. Microbiol.* **2007**, *56*, 71. [PubMed]
16. Tosa, T.; Sato, T.; Mori, T.; Chibata, I. Basic Studies for Continuous Production of L-aspartic Acid by Immobilized *Escherichia coli* Cells. *Appl. Environ. Microbiol.* **1974**, *27*, 886–889. [CrossRef]
17. Millipore Sigma. Microbiological Culture Media. Available online: https://www.sigmaaldrich.com/united-states.html (accessed on 14 February 2020).

18. Piao, X.; Wang, L.; Lin, B.; Chen, H.; Liu, W.; Tao, Y. Metabolic Engineering of *Escherichia coli* for Production of L-aspartate and Its Derivative β-alanine with High Stoichiometric Yield. *Metab. Eng.* **2019**, *54*, 244–254. [CrossRef] [PubMed]
19. Xu, Q.; Li, S.; Huang, H.; Wen, J. Key Technologies for the Industrial Production of Fumaric Acid by Fermentation. *Biotechnol. Adv.* **2012**, *30*, 1685–1696. [CrossRef] [PubMed]
20. Engel, C.C.R.; Straathof, A.J.J.; Zijlmans, T.W.; Van Gulik, W.M.; Van Der Wielen, L.A.M. Fumaric Acid Production by Fermentation. *Appl. Microbiol. Biotechnol.* **2008**, *78*, 379–389. [CrossRef] [PubMed]